Your session is about to expire
← Back to Search
Unknown
TTHX1114 for Fuchs' Dystrophy (OPTIC Trial)
Phase 2
Waitlist Available
Research Sponsored by Trefoil Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28
Awards & highlights
OPTIC Trial Summary
This trial is for a new medication called TTHX1114, which is for patients with a certain eye condition called CED. The trial is open label, which means that both the doctors and patients will know which medication is being given.
OPTIC Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 28
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Specular Microscopy
Secondary outcome measures
Pachymetry
OPTIC Trial Design
1Treatment groups
Experimental Treatment
Group I: TTHX1114 weekly x 5Experimental Treatment1 Intervention
TTHX1114 via IC injection weekly x 5
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TTHX1114
2021
Completed Phase 2
~50
Find a Location
Who is running the clinical trial?
Trefoil Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
79 Total Patients Enrolled
1 Trials studying Fuchs' Dystrophy
49 Patients Enrolled for Fuchs' Dystrophy
Thomas TremblayStudy DirectorTrefoil Therapeutics.com
2 Previous Clinical Trials
57 Total Patients Enrolled
1 Trials studying Fuchs' Dystrophy
49 Patients Enrolled for Fuchs' Dystrophy
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a condition called uveitis.You have had eye cancer in the past (including melanoma).You are 18 years of age or older.\nYou are a woman of childbearing potential (WOCBP).You have experienced a severe allergic reaction or intolerance to any medication, food or substance.Your other eye has a vision of 20/100 or better.You have any other medical condition that, according to the researcher, could make you more at risk, make it difficult to understand the study results or make it hard for you to follow the study requirements.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Research Study Groups:
This trial has the following groups:- Group 1: TTHX1114 weekly x 5
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the TTHX1114 FDA status?
"TTHX1114 is in Phase 2 of clinical trials, so there is some evidence that it is safe but none yet regarding whether or not the medication is effective."
Answered by AI
Are people with the required qualifications able to participate in this research currently?
"According to the website, this particular trial is not actively looking for patients right now. The listing was put up on November 30th 2021 and updated January 21st of this year. Although there are no open enrolments at the moment, there are 3 other trials that are currently accepting patients."
Answered by AI
Who else is applying?
What state do they live in?
Arkansas
How old are they?
18 - 65
What site did they apply to?
Trefoil Study Site
What portion of applicants met pre-screening criteria?
Met criteria
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger